相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Highly Sensitive Blocker Displacement Amplification and Droplet Digital PCR Reveal Low-Level Parental FOXF1 Somatic Mosaicism in Families with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins
Justyna A. Karolak et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
Christian Menzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer
Takeo Fujii et al.
EUROPEAN JOURNAL OF CANCER (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
Gabriele Romano et al.
CANCER DISCOVERY (2018)
Melanoma treatment in review
Beatriz Domingues et al.
IMMUNOTARGETS AND THERAPY (2018)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification
Lucia R. Wu et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Clinicopathological characteristics associated with BRAFK601E and BRAFL597 mutations in melanoma
Mark Voskoboynik et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Mack Y. Su et al.
PLOS MEDICINE (2016)
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
Michael T. Tetzlaff et al.
HUMAN PATHOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma
S. Parakh et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Boris C. Bastian
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing
Stephen Q. Wong et al.
BMC MEDICAL GENOMICS (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
L. Heinzerling et al.
BRITISH JOURNAL OF CANCER (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
The Immune Score as a New Possible Approach for the Classification of Cancer
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Jill C. Rubinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
分享论文
